Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) have received an average broker rating score of 1.00 (Strong Buy) from the four analysts that cover the stock, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy rating.

Brokerages have set a 1 year consensus price objective of $23.67 for the company, according to Zacks. Zacks has also given Mersana Therapeutics an industry rank of 115 out of 265 based on the ratings given to its competitors.

MRSN has been the topic of several recent research reports. J P Morgan Chase & Co initiated coverage on Mersana Therapeutics in a research report on Monday, July 24th. They set an “overweight” rating and a $23.00 target price on the stock. Wedbush reaffirmed an “outperform” rating and set a $25.00 target price on shares of Mersana Therapeutics in a research report on Monday, July 24th. Leerink Swann initiated coverage on Mersana Therapeutics in a research report on Monday, July 24th. They set an “outperform” rating and a $23.00 target price on the stock. Finally, Cowen and Company initiated coverage on Mersana Therapeutics in a research report on Monday, July 24th. They set an “outperform” rating on the stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of New York Mellon Corp bought a new stake in Mersana Therapeutics during the 3rd quarter valued at $231,000. Goldman Sachs Group Inc. bought a new stake in Mersana Therapeutics during the 2nd quarter valued at $699,000. Tudor Investment Corp ET AL bought a new stake in Mersana Therapeutics during the 2nd quarter valued at $989,000. Citadel Advisors LLC bought a new stake in Mersana Therapeutics during the 2nd quarter valued at $179,000. Finally, FMR LLC bought a new stake in Mersana Therapeutics during the 2nd quarter valued at $23,926,000. 74.65% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Mersana Therapeutics, Inc. (MRSN) Receives Consensus Recommendation of “Strong Buy” from Analysts” was published by American Banking News and is owned by of American Banking News. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/11/11/mersana-therapeutics-inc-mrsn-receives-consensus-recommendation-of-strong-buy-from-analysts.html.

Mersana Therapeutics (NASDAQ MRSN) traded down $0.10 on Friday, reaching $17.00. The company’s stock had a trading volume of 8,200 shares, compared to its average volume of 72,163. Mersana Therapeutics has a one year low of $12.71 and a one year high of $21.01.

Mersana Therapeutics (NASDAQ:MRSN) last released its quarterly earnings data on Thursday, November 9th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.13. The firm had revenue of $6.27 million for the quarter, compared to analysts’ expectations of $3.93 million. equities analysts predict that Mersana Therapeutics will post -2.94 earnings per share for the current fiscal year.

About Mersana Therapeutics

Mersana Therapeutics, Inc is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug’s chances of attacking cancers.

Get a free copy of the Zacks research report on Mersana Therapeutics (MRSN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Mersana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.